Autopsy report · NCT02361177

Role of Oxytocin in Telling and Detecting Lies

“Drug not available”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Early Phase 1

Sponsor

University of Texas at Austin

Sponsor type

University, hospital or other

Conditions

Dyssocial Behavior

Interventions

Oxytocin

Participants

0

Trials that died the same way

• Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome
  “Drug unavailable” (93% match in meaning)
• TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
  “Drug no longer available” (89% match in meaning)
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (84% match in meaning)
• Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
  “Drug was not available.” (83% match in meaning)
• Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD
  “Drug availability” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.